April 2026
The Cornell Chronicle, Cornell University’s biggest news platform, recently published a feature on a new publication in PNAS from Paula Cohen’s lab. The research article, “Meiotic prophase I disruption as a strategy for nonhormonal male contraception using small-molecule inhibitor JQ1,” demonstrates that JQ1, a small-molecule inhibitor, can act as a male contraceptive by killing cells during prophase I of meiosis, and that the process is reversible upon drug removal. Incredibly, mice treated with JQ1 produced viable sperm and healthy offspring just six weeks after stopping the drug. To learn more about these exciting findings and their implications for the future of male contraceptive medicine, read the Chronicle article, “Breakthrough takes big step toward safe, reversible male contraception.”
